|
|
 Previous Article | Table of Contents | Next Article 
Translocation (14;18)-positive cells are present in the circulation of the
majority of patients with localized (stage I and II) follicular non-
Hodgkin's lymphoma
AC Lambrechts, PE Hupkes, LC Dorssers and MB van't Veer
Department of Molecular Biology, Dr Daniel Den Hoed Cancer Center,
Rotterdam, The Netherlands.
Stage I and II follicular non-Hodgkin's lymphoma (NHL) is clinically
defined as a localized disease. To study the possibility that this disease
is in fact disseminated, we used the sensitive polymerase chain reaction
(PCR) method using translocation (14;18) as marker. Samples from 21
patients who were clinically diagnosed with stage I or II follicular NHL
were analyzed for the presence of t(14;18)-positive cells using PCR. We
analyzed (1) the diagnostic lymph node biopsy and (2) the peripheral blood
or bone marrow samples from these patients. Translocation (14;18) cells
were detected in the diagnostic lymph node biopsies of 12 patients. In 9 of
these patients, t(14;18)-positive cells were detected in peripheral blood
and/or bone marrow samples at diagnosis and/or after therapy. Thus, in 75%
of the follicular NHL patients carrying the t(14;18) as a marker for
lymphoma cells, t(14;18)- positive cells were detected in peripheral blood
and bone marrow at diagnosis and after therapy. Our results show that
t(14;18)-positive cells can be detected in the circulation of patients with
stage I and II follicular NHL, indicating that, although diagnosed as
localized, the disease is disseminated.
Volume 82,
Issue 8,
pp. 2510-2516,
10/15/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. P. Siakantaris, G. A. Pangalis, E. Dimitriadou, F. N. Kontopidou, T. P. Vassilakopoulos, C. Kalpadakis, S. Sachanas, X. Yiakoumis, P. Korkolopoulou, M.-C. Kyrtsonis, et al.
Early-Stage Gastric MALT Lymphoma: Is It a Truly Localized Disease?
Oncologist,
February 1, 2009;
14(2):
148 - 154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. K. Weinberg, W. Z. Ai, M. R. Mariappan, C. Shum, R. Levy, and D. A. Arber
''Minor'' BCL2 Breakpoints in Follicular Lymphoma: Frequency and Correlation with Grade and Disease Presentation in 236 Cases
J. Mol. Diagn.,
September 1, 2007;
9(4):
530 - 537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Biagi and J. F. Seymour
Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation
Blood,
May 29, 2002;
99(12):
4265 - 4275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Summers, L. K. Goff, A. G. Wilson, R. K. Gupta, T. A. Lister, and J. Fitzgibbon
Frequency of the Bcl-2/IgH Rearrangement in Normal Individuals: Implications for the Monitoring of Disease in Patients With Follicular Lymphoma
J. Clin. Oncol.,
January 15, 2001;
19(2):
420 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Corcione, L. Ottonello, G. Tortolina, P. Facchetti, I. Airoldi, R. Guglielmino, P. Dadati, M. Truini, S. Sozzani, F. Dallegri, et al.
Stromal Cell-Derived Factor-1 as a Chemoattractant for Follicular Center Lymphoma B Cells
J Natl Cancer Inst,
April 19, 2000;
92(8):
628 - 635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
